Badanie skuteczności i bezpieczeństwa ropeginterferonu alfa-2b u pacjentów z przewlekłą białaczką szpikową leczonych bosutynibem od diagnozy

Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. This study is focused on evaluating the effectiveness and safety of a treatment combination for patients newly diagnosed with CML. The treatment involves two medications: bosutinib, which is a type of drug known as a tyrosine kinase inhibitor, and ropeginterferon alfa-2b, a long-acting form of interferon given as an injection. The goal of the study is to see if adding ropeginterferon alfa-2b to bosutinib can help more patients achieve a deep molecular response, which means a significant reduction in cancer cells, and potentially allow them to stop treatment while remaining in remission.

Participants in the study will be randomly assigned to receive either the combination of bosutinib and ropeginterferon alfa-2b or bosutinib alone. The study will monitor the patients over time to compare the effectiveness of the treatments in achieving a deep molecular response. The study will also look at the safety of the treatments by tracking any side effects experienced by the participants. The treatment with bosutinib is taken orally, while ropeginterferon alfa-2b is administered through a subcutaneous injection, which means it is injected under the skin.

The study aims to provide valuable information on whether the combination of these two treatments can improve outcomes for patients with CML. By understanding the effects of adding ropeginterferon alfa-2b to the standard treatment with bosutinib, researchers hope to increase the number of patients who can achieve and maintain remission without ongoing treatment. The study will continue to collect data over several years to assess the long-term benefits and safety of the treatment combination.